Clinical research company IQVIA (NYSE: IQV) will be announcing earnings results tomorrow before market hours. Here’s what to look for.
IQVIA beat analysts’ revenue expectations by 1% last quarter, reporting revenues of $3.90 billion, up 4.3% year on year. It was a mixed quarter for the company, with constant currency revenue in line with analysts’ estimates.
Is IQVIA a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting IQVIA’s revenue to grow 1.7% year on year to $3.93 billion, slowing from the 3.5% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $3.11 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. IQVIA has only missed Wall Street’s revenue estimates once over the last two years, exceeding top-line expectations by 0.8% on average.
Looking at IQVIA’s peers in the life sciences tools & services segment, some have already reported their Q4 results, giving us a hint as to what we can expect. and Bio-Techne reported revenues up 9%, topping estimates by 4.2%.
Read our full analysis of Azenta’s results here and Bio-Techne’s results here.
There has been positive sentiment among investors in the life sciences tools & services segment, with share prices up 2.7% on average over the last month. IQVIA’s stock price was unchanged during the same time and is heading into earnings with an average analyst price target of $246.82 (compared to the current share price of $201).
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.